Loading stock data…
$2.22-0.04 (-1.77%)
Cerus Corporation operates as a biomedical products company.
Cerus Corporation in the Healthcare sector is trading at $2.22 with a market capitalization of $447M. Wall Street consensus targets $5.12 (4 analysts), implying a +130.8% move over the next 12 months. The stock is currently 36% below its 52-week high of $3.47, remaining 9.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $57.44M↑ | $53.66M↓ | $57.75M↑ | $52.70M↑ | $52.45M |
| Gross Profit | $29.53M↑ | $27.89M↓ | $29.75M↑ | $28.14M↓ | $28.98M |
| Operating Income | -$1.86M↓ | -$354,000↑ | -$641,000↓ | $1.24M↑ | -$3.42M |
| Net Income | -$2.94M↓ | -$1.64M↑ | -$2.18M↓ | -$19,000↑ | -$5.71M |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling...